Refoxy Pharmaceuticals, a Berlin, Germany-based preclinical biotech company developing small molecule activators of the FOXO3 transcription factor for the treatment of age-related diseases, raised €9.1M in Seed extension funding.
The round was led by Boehringer Ingelheim Venture Fund (BIVF), and joined by Apollo Heath Ventures, NRW.Venture, and High-Tech Gründerfonds (HTGF).
The company intends to use the funds to advance the development of new therapeutic medicines in diverse indications, starting with idiopathic pulmonary fibrosis (IPF).
Co-founded by Dr. Victor Bustos and Prof. Wolfgang Link in partnership with Apollo Health Ventures, Refoxy is a biotech company developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Its discovery platform, F.act finder (FOXO activator finder), delivers molecules that specifically modulate FOXO3 and elicit unique therapeutic effects.
The company is developing a pipeline of therapeutics, with an initial focus on fibrotic disorders, particularly IPF.
FinSMEs
04/12/2024